login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VIKING THERAPEUTICS INC (VKTX) Stock News
USA
-
Nasdaq
- NASDAQ:VKTX -
US92686J1060
-
Common Stock
36.72
USD
-0.36 (-0.97%)
Last: 12/15/2025, 2:54:08 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VKTX Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: The Motley Fool
- Mentions:
NVDA
AMZN
META
CRWV
...
My Top 10 Stocks to Buy for 2026
4 days ago - By: The Motley Fool
- Mentions:
AMZN
CCL
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026
5 days ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
GPCR
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
5 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
6 days ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
GPCR
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
a month ago - By: Stocktwits
- Mentions:
MTSR
PFE
NVO
LLY
...
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios
11 days ago - By: Benzinga
What's Up With The Jump In Viking Therapeutics Stock?
11 days ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
ADVM
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
12 days ago - By: Zacks Investment Research
- Mentions:
LLY
NVO
AMGN
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
13 days ago - By: Zacks Investment Research
- Mentions:
LLY
PFE
NVO
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
14 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
17 days ago - By: Zacks Investment Research
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
18 days ago - By: Zacks Investment Research
- Mentions:
REGN
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
18 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
19 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
20 days ago - By: Stocktwits
- Mentions:
NVO
LLY
HIMS
HSBC
...
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’
20 days ago - By: Viking Therapeutics, Inc.
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
21 days ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
21 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
24 days ago - By: Zacks Investment Research
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?
25 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
a month ago - By: Viking Therapeutics, Inc.
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
a month ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
AMGN
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
a month ago - By: Benzinga
- Mentions:
STUB
APP
AMZN
INSM
...
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves
a month ago - By: Zacks Investment Research
- Mentions:
LLY
NVO
AMGN
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
a month ago - By: Stocktwits
- Mentions:
PFE
UNH
LLY
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play
a month ago - By: Zacks Investment Research
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
a month ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
a month ago - By: Zacks Investment Research
- Mentions:
LLY
NVO
ADVM
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Please enable JavaScript to continue using this application.